Ensysce Biosciences closes USD 2 million convertible preferred stock private placement

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC

0.00
  • Ensysce Biosciences closed a $2 million convertible preferred stock financing under a November 2025 commitment for up to $20 million over 24 months.
  • Terms include a fixed conversion price of $0.55 per share.
  • Structure also provides an alternate conversion price tied to average common stock prices before conversion.
  • Financing includes 100% warrant coverage with an 18-month term.
  • Additional 100% warrant coverage carries a five-year term.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.